Report of the working group on bacterial meningitis and related conditions.

Hdl Handle:
http://hdl.handle.net/10147/266300
Title:
Report of the working group on bacterial meningitis and related conditions.
Authors:
Department of Health (DoH)
Publisher:
Department of Health (DoH)
Issue Date:
Jan-1997
URI:
http://hdl.handle.net/10147/266300
Item Type:
Report
Language:
en
Description:
Bacterial meningitis and septicaemia are systemic infections caused by a variety of organisms, the most common being Neisseria meningitidis, Baemophilus influenzae type B, (Bib) and Streptococcus pneumoniae The epidemiology of these conditions in the western world has been well described. This is particularly so in repect of the most commonly occurring of these infections in this country meningoccal disease! This infection is spread by direct contact, can affect any age group but is concentrated mainly in infancy and early childhood, occurs mainly sporadically but occasionally in epidemic form, occurs throughout the year but peaks during the winter months, and carries a case fatality rate of up to 10%. The most common clinical presentations are meningitis alone, septicaemia alone, and a combination of the two. Early diagnosis and effective antibiotic treatment of cases are of paramount importance in managing the condition and the effective implementation of chemo and immunoprophylactic strategies are required to prevent its further spread. A vaccine is available against invasive Hib disease and its introduction into routine childhood vaccination programmes in recent years has resulted in a significant fall in incidence of this condition to the point of eradication in some countries. Vaccines are also available against meningoccus type A and C and should be given to close contacts of cases caused by these organisms. However, as there is little immunological response in children under 18 months to the group C component and under three months to the group A component, vaccination is not recommended under these ages. There is no available vaccine effective against group meningoccal B organisms but intensive research and development work is being carried out world-wide in an effort to develop a safe and effective B vaccine and to further strengthen the effectiveness of the A & C vaccines now available. Significant progress is being reported and it is hoped that new and improved vaccines will be available for use in the next few years.
Keywords:
MENINGITIS; INFECTION CONTROL

Full metadata record

DC FieldValue Language
dc.contributor.authorDepartment of Health (DoH)en_GB
dc.date.accessioned2013-01-21T11:35:44Z-
dc.date.available2013-01-21T11:35:44Z-
dc.date.issued1997-01-
dc.identifier.urihttp://hdl.handle.net/10147/266300-
dc.descriptionBacterial meningitis and septicaemia are systemic infections caused by a variety of organisms, the most common being Neisseria meningitidis, Baemophilus influenzae type B, (Bib) and Streptococcus pneumoniae The epidemiology of these conditions in the western world has been well described. This is particularly so in repect of the most commonly occurring of these infections in this country meningoccal disease! This infection is spread by direct contact, can affect any age group but is concentrated mainly in infancy and early childhood, occurs mainly sporadically but occasionally in epidemic form, occurs throughout the year but peaks during the winter months, and carries a case fatality rate of up to 10%. The most common clinical presentations are meningitis alone, septicaemia alone, and a combination of the two. Early diagnosis and effective antibiotic treatment of cases are of paramount importance in managing the condition and the effective implementation of chemo and immunoprophylactic strategies are required to prevent its further spread. A vaccine is available against invasive Hib disease and its introduction into routine childhood vaccination programmes in recent years has resulted in a significant fall in incidence of this condition to the point of eradication in some countries. Vaccines are also available against meningoccus type A and C and should be given to close contacts of cases caused by these organisms. However, as there is little immunological response in children under 18 months to the group C component and under three months to the group A component, vaccination is not recommended under these ages. There is no available vaccine effective against group meningoccal B organisms but intensive research and development work is being carried out world-wide in an effort to develop a safe and effective B vaccine and to further strengthen the effectiveness of the A & C vaccines now available. Significant progress is being reported and it is hoped that new and improved vaccines will be available for use in the next few years.en_GB
dc.language.isoenen
dc.publisherDepartment of Health (DoH)en_GB
dc.subjectMENINGITISen_GB
dc.subjectINFECTION CONTROLen_GB
dc.titleReport of the working group on bacterial meningitis and related conditions.en_GB
dc.typeReporten
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.